Pneumology - Original Articles Open access

Trajectory of the response to bronchodilator and respiratory outcomes in adults with asthma-like symptoms

Authors

Published
17 March 2025
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2025.3116

Abstract

In the real world, health professionals need to care for individuals with asthma-like symptoms who have a persistently negative bronchodilator response (BDR). Little is known about the evolution of symptoms and lung function of these individuals because they are usually excluded from studies on asthma. The aim of this study was to evaluate whether individuals with asthma-like symptoms but with a persistently negative BDR have a different evolution of symptoms and lung function compared to individuals with asthma proven by positive BDR. This prospective cohort study included adults with asthma-like symptoms. Individuals participated in two visits, 12 months apart. They responded to questionnaires and underwent a spirometry test. In individuals without airway obstruction in the first visit, those with asthma-like symptoms and persistently negative BDR were less likely to lose forced expiratory volume in the first second during follow-up or progress to airway obstruction at the final visit compared to individuals with asthma proven by positive BDR. Among individuals with airway obstruction at baseline, those with asthma-like symptoms and persistently negative BDR were less likely to resolve the airway obstruction during follow-up compared to individuals with asthma proven by positive BDR. In individuals with proven asthma, the emergence or persistence of positive BDR during follow-up was accompanied by a worsening of asthma outcomes compared to the remission of positive BDR. Thus, BRD is an accessible marker of disease progression in individuals with asthma-like symptoms. In individuals with asthma proven by positive BDR, the trend in BDR was associated with the evolution of symptoms and lung function.

Keywords

Ethics Approval

The institutional review board of the Jundiaí School of Medicine approved the study, approval number 5.221.754.

References

  1. Ijpma G, Kachmar L, Matusovsky OS, et al. Human trachealis and main bronchi smooth muscle are normoresponsive in asthma. Am J Respir Crit Care Med 2015;191:884-93. DOI: https://doi.org/10.1164/rccm.201407-1296OC
  2. Khan MA. Inflammation signals airway smooth muscle cell proliferation in asthma pathogenesis. Multidiscip Respir Med 2013;8:11. DOI: https://doi.org/10.1186/2049-6958-8-11
  3. Regamey N, Ochs M, Hilliard TN, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2008;177:837-43. DOI: https://doi.org/10.1164/rccm.200707-977OC
  4. Muniz IS, Ponte EV, Lima VB, Cruz ÁA. Irreversible airway obstruction in asthma: a risk factor for severe exacerbations in spite of proper treatment. J Asthma 2016;53;801-7. DOI: https://doi.org/10.3109/02770903.2016.1155220
  5. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J 2021;59:2102730. DOI: https://doi.org/10.1183/13993003.02730-2021
  6. Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J 2019;54:1900561. DOI: https://doi.org/10.1183/13993003.00561-2019
  7. Cavallazzi RS, Polivka BJ, Beatty BL, et al. Current bronchodilator responsiveness criteria underestimate asthma in older adults. Respir Care 2020;65:1104-11. DOI: https://doi.org/10.4187/respcare.07132
  8. Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol 2003;90:194-8. DOI: https://doi.org/10.1016/S1081-1206(10)62140-0
  9. Puckett JL, Taylor RW, Leu SY, et al. An elevated bronchodilator response predicts large airway inflammation in mild asthma. Pediatr Pulmonol 2010;45:174-81. DOI: https://doi.org/10.1002/ppul.21172
  10. Goleva E, Hauk PJ, Boguniewicz J, et al. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 2007;120:1065-72. DOI: https://doi.org/10.1016/j.jaci.2007.07.042
  11. Roxo JP, Ponte EV, Ramos DC, et al. Portuguese-language version of the asthma control test. J Bras Pneumol 2010;36:159-66. [Article in Portuguese]. DOI: https://doi.org/10.1590/S1806-37132010000200002
  12. Theodoro EE, Rocha DGD, Bertolino JR, et al. Evaluating the effect of antidepressants on the relationship between depression and asthma. Respir Med 2023;207:107099. DOI: https://doi.org/10.1016/j.rmed.2022.107099
  13. Silva JN, Rocha A, de Souza IA, et al. Does peripheral blood eosinophil count predict lung function improvement in adult individuals with asthma? Ann Allergy Asthma Immunol 2021;127:388-9. DOI: https://doi.org/10.1016/j.anai.2021.05.024
  14. Almeida PC, Ponte EV, Souza-Machado A, Cruz AA. Longitudinal trends in clinical characteristics and lung function of patients with severe asthma under treatment in Brazil. BMC Pulm Med 2016;16:141. DOI: https://doi.org/10.1186/s12890-016-0302-5
  15. Wei J, Ma L, Wang J, et al. Airway reversibility in asthma and phenotypes of Th2 biomarkers, lung function and disease control. Allergy Asthma Clin Immunol 2018;14:89. DOI: https://doi.org/10.1186/s13223-018-0315-0
  16. Ponte EV, Lima A, Almeida PCA, et al. Age is associated with asthma phenotypes. Respirology 2017;22:1558-63. DOI: https://doi.org/10.1111/resp.13102
  17. Ponte EV, Stelmach R, Franco R, et al. Age is not associated with hospital admission or uncontrolled symptoms of asthma if proper treatment is offered. Int Arch Allergy Immunol 2014;165:61-7. DOI: https://doi.org/10.1159/000367924
  18. Bezerra de Menezes M, Ponte EV, Bertagni Mingotti CF, et al. Provision of inhaled corticosteroids is associated with decrease in hospital admissions in Brazil: a longitudinal nationwide study. Respir Med 2020;166:105950. DOI: https://doi.org/10.1016/j.rmed.2020.105950
  19. Ponte EV, Rocha DGD, Guinossi RM, et al. Evaluating the relationship between the type of rescue medication and the adequacy of asthma maintenance therapy. Respir Med 2023;217:107364. DOI: https://doi.org/10.1016/j.rmed.2023.107364
  20. Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med 2017;195:302-13. DOI: https://doi.org/10.1164/rccm.201602-0419OC
  21. Nuijsink M, Hop WC, Sterk PJ, et al. Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial. Eur Respir J 2007;30:457-66. DOI: https://doi.org/10.1183/09031936.00111806
  22. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-51. DOI: https://doi.org/10.1164/ajrccm.159.4.9806052
  23. Ashenhurst JR, Nhan H, Shelton JF, et al. Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and health care engagement among direct-to-consumer recipients of a personalized genetic risk report. Chest 2022;161:373-81. DOI: https://doi.org/10.1016/j.chest.2021.09.041
  24. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60:2101499. DOI: https://doi.org/10.1183/13993003.01499-2021

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.